Bone physiology
Most common disorder involving bone
Osteoporosis
Osteoporosis characteristics
Drugs used to treat Osteoporosis
Drugs that inhibit Osteoclasts: anti-resorptive
Drugs that promote osteoblasts: anabolic
Drugs that inhibit osteoclasts (4)
Bisphosphonates example
Alendronate
Mechanism of Bisphosphonates
Promote apoptosis of osteoclasts
Other uses of BPs (Alendronate)
Hypercalcemia: inhibit bone reabsorption, reduces release of Calcium into the blood
BPs unusual distribution
Concentrate in bone: can remain attached to bone for several months, Osteoclasts activity (release of acids) releases BPs slowly over time, can take weekly: One formulation, zolendronic acid, administered IV once/year
Administration of BP’s
Most administered Orally
- low oral bioavailability, food and mineral like calcium reduce absorption
- take on empty stomach
Other than Zolendronic acid: intravenous infusion
BPs adverse effects
Main serious Issue with BPs
Hormone therapy
Estrogens promote bone
Negative effects of Estrogen
- increased risk to thrombosis
Raloxifene
Acts as an estrogen agonist in bone
- inhibits reabsorption
Adverse effects of Raloxifene
Hot flashes
Leg cramps
Increases risk of thrombosis
Role of RANKL
Receptor Activator of Nuclear factor Kappa-B Ligand
RANKL inhibitor example
Denosumab
Denosumab mechanism
- inhibits osteoclasts activity
Denosumab characteristics
- administered by injection
RANKL inhibitors adverse effects
Calcitonin mechanism
Calcitonin uses
More commonly for treating pain from osteoporotic fractures
Administered as an injection
Calcitonin adverse effects